In other glioblastoma sub-cohorts, the clinical utility of MGMT testing is lower and at present does not have direct implications for clinical management [24], although knowledge of the MGMT promoter methylation status may support prognostic considerations that influence indirectly patient management. Here, MGMT is linked to glioblastoma.